Hospital General Universitario De Valencia

Hospital General Universitario De Valencia is investigating novel anticoagulation strategies for atrial fibrillation, aiming to lower the risk of stroke and systemic embolism through a direct comparison of new agents with established therapy.

• Atrial fibrillation management
• Prevention of cardioembolic events
• Evaluation of alternative anticoagulants
• Stroke risk reduction outcomes

Across its portfolio of 13 trials, the site engages 72 investigators, integrating cardiovascular research within its broader clinical program.

The department conducts endocrine studies focused on chronic hypoparathyroidism, testing a recombinant peptide to enhance calcium homeostasis and improve patient well‑being.

• Chronic hypoparathyroidism treatment
• Calcium and vitamin D regulation
• Hormone replacement strategies
• Bone health and metabolic balance

These investigations complement the hospital’s efforts in metabolic health and support a multidisciplinary approach to hormonal disorders.

Researchers are evaluating targeted biologics such as rocatinlimab in combination with topical therapies for moderate‑to‑severe atopic dermatitis, seeking faster skin clearance and sustained disease control.

• Atopic dermatitis biologic therapy
• Combination with corticosteroids or calcineurin inhibitors
• Eczema Area and Severity Index improvement
• Immune pathway modulation

This work leverages the site’s expertise in immune modulation, aligning with its oncology immunotherapy programs.

A core research focus is on advanced solid tumors, where innovative immunotherapies including nivolumab, relatlimab, and botensilimab are studied to extend progression‑free survival and improve response rates in melanoma, colorectal, and ovarian cancers.

• Advanced melanoma (treated and refractory)
• Metastatic colorectal cancer with dMMR
• Advanced epithelial ovarian cancer
• Unresectable melanoma treatment
• Adjuvant therapy for resected melanoma

The oncology unit leads 13 active trials, reflecting a strong commitment to advancing cancer care.

Clinical studies target obesity and related metabolic conditions, evaluating a multi‑agonist peptide retatrutide for weight reduction and exploring its potential benefits for knee osteoarthritis.

• Obesity and overweight management
• Knee osteoarthritis symptom relief
• Metabolic syndrome intervention
• Weight‑loss efficacy assessment

By integrating metabolic research with oncology, the site offers patients access to cutting‑edge therapeutic options.